美罗华
B细胞激活因子
重症肌无力
医学
抗体
免疫学
效价
内科学
生物标志物
胃肠病学
B细胞
生物
生物化学
作者
Yangjie Zhou,Chong Yan,Xinyu Gu,Lei Zhou,Jun Lü,Wenhua Zhu,Xiao Huan,Sushan Luo,Huahua Zhong,Jie Lin,Jiahong Lu,Chongbo Zhao,Jianying Xi
摘要
Abstract Introduction/Aims The study aims to investigate the short‐term efficacy of low‐dose rituximab and its effect on immunological biomarker levels in myasthenia gravis (MG) patients with antibodies against muscle‐specific tyrosine kinase (MuSK‐MG). Methods Twelve MuSK‐MG patients were enrolled in this prospective, open‐label, self‐controlled pilot study. Clinical severity was evaluated at baseline and 6 mo after a single rituximab treatment (600 mg). B lymphocyte subtypes, MuSK antibody titers, together with levels of immunoglobulins, serum B‐cell activating factor (BAFF), a proliferation‐inducing ligand (APRIL), soluble CD40L, and four exosomal microRNAs were evaluated. A correlation matrix to reveal pairwise relationships among above variables was also generated. Results The single rituximab treatment significantly lowered the clinical severity scores and reduced daily dosage of prednisone ( P = .032) at 6 mo. MuSK antibody titers decreased ( P = .035) without significant changes in immunoglobulin levels. Serum BAFF level increased ( P = .010), which negatively correlated with the percentages of B cells in lymphocytes as well as clinical severity. Additionally, serum exosomal miR‐151a‐3p showed a reduction of 28.1% ( P = .031). Discussion We confirmed the clinical efficacy of low‐dose rituximab in MuSK‐MG, accompanied by a decrease in MuSK antibody titers and an increase in serum BAFF. Serum BAFF levels negatively correlated with B‐cell counts as well as clinical severity.
科研通智能强力驱动
Strongly Powered by AbleSci AI